Civica Inc. announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica's affordable insulins. As previously announced, Civica plans to produce three insulin biosimilars glargine, lispro and aspart each of which will be available both in vials and prefilled pens, and sell the insulins at significantly lower prices than insulins currently on the market. To ensure redundancy of supply, Ypsomed will provide injector dosing pens from their two manufacturing facilities in Switzerland and Germany.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
405 CHF | -5.59% | -4.14% | +33.66% |
Jun. 20 | Ypsomed Partner Secures US FDA Nod for Automated Insulin Delivery Algorithm | MT |
Jun. 12 | German Pharmaceutical Medac Picks Ypsomed Autoinjector for Methotrexate Pen Relaunch | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.66% | 6.54B | |
-4.90% | 179B | |
-1.36% | 100B | |
-7.64% | 46.16B | |
+13.42% | 44.81B | |
+9.63% | 44.38B | |
+13.63% | 29.53B | |
+21.25% | 25.83B | |
-7.12% | 23.97B | |
+4.03% | 22.5B |
- Stock Market
- Equities
- YPSN Stock
- News Ypsomed Holding AG
- Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative